复星医药宣布其子公司研发的FKC289注射液,已正式获得国家药品监督管理局(NMPA)批准,将开展I/II期临床试验。这一进展标志着该创新药物在临床开发阶段迈出了关键一步。
复星医药宣布其子公司研发的FKC289注射液,已正式获得国家药品监督管理局(NMPA)批准,将开展I/II期临床试验。这一进展标志着该创新药物在临床开发阶段迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.